Vaxart, Inc. 16,000,000 Shares of Common Stock Underwriting AgreementLock-Up Agreement • June 8th, 2023 • Vaxart, Inc. • Biological products, (no disgnostic substances) • New York
Contract Type FiledJune 8th, 2023 Company Industry JurisdictionVaxart, Inc., Inc., a Delaware corporation (the "Company"), proposes to issue and sell to the several underwriters named in Schedule A (the "Underwriters") an aggregate of (a) 16,000,000 shares of common stock (the "Firm Shares"), par value $0.0001 per share, of the Company (the "Common Stock"). The amount and form of the Firm Shares to be purchased by the Underwriters is set forth opposite its name on Schedule A hereto. The Company also proposes to sell to the Underwriters, at the option of the Underwriters, up to an additional 2,400,000 shares of Common Stock (the "Option Shares"). The Firm Shares and the Option Shares are collectively referred to herein as the "Shares".